2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline has been researched along with transforming growth factor alpha in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ryu, DY; Snyderwine, EG; Thorgeirsson, SS; Weidner, V | 1 |
| Calvisi, DF; Conner, EA; Factor, VM; Ladu, S; Thorgeirsson, SS | 1 |
2 other study(ies) available for 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline and transforming growth factor alpha
| Article | Year |
|---|---|
Carcinogenicity and mutagenicity of heterocyclic amines in transgenic mouse models.
Topics: Animals; DNA, Complementary; Genes, myc; Mice; Mice, Transgenic; Mutagenesis; Mutagens; Neoplasms, Experimental; Quinolines; Quinoxalines; Transforming Growth Factor alpha | 1999 |
Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice.
Topics: alpha-Fetoproteins; Animals; beta Catenin; Cell Cycle Proteins; Cytoskeletal Proteins; Disease Models, Animal; DNA-Binding Proteins; E2F Transcription Factors; E2F1 Transcription Factor; Gene Deletion; Gene Frequency; Genes, myc; Genomic Instability; Liver Neoplasms; Loss of Heterozygosity; Mice; Mice, Transgenic; Mutation; Phenotype; Quinoxalines; Trans-Activators; Transcription Factors; Transforming Growth Factor alpha | 2004 |